Odonate Therapeutics, Inc. (ODT) |
| 1.12 -0.05 (-4.27%) 04-24 15:47 |
| Open: | 1.16 |
| High: | 1.2 |
| Low: | 1.1107 |
| Volume: | 716,440 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.41 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 28.41 |
| 52w Low: | 0.85 |
Odonate Therapeutics, Inc. functions as a pharmaceutical enterprise, dedicating its efforts to the creation of innovative therapeutic agents for cancer treatment. A prominent compound within its development pipeline is tesetaxel, an orally administered chemotherapy drug. This agent is currently advancing through Phase III clinical trials, specifically under investigation for its application in individuals with metastatic breast cancer. Established in 2013, the company's operations are headquartered in New York, New York.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Tue, 27 Jul 2021
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 - Business Wire
Mon, 22 Mar 2021
Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel - Business Wire
Thu, 17 Dec 2020
New York : BeyondSpring Appoints Dr. Jeffrey Vacirca to Board - newyork.citybuzz.co
Sat, 17 Oct 2020
ROSEN, A LEADING LAW FIRM, Reminds Odonate Therapeutics, - GlobeNewswire
Mon, 01 Oct 2018
SB 826: Nearly 100 California companies must add women to board of directors - CBS News
Sat, 29 Aug 2026
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
